Cellectis SA ADR CLLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
-
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
-
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
-
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
-
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Trading Information
- Previous Close Price
- $1.10
- Day Range
- $1.10–1.15
- 52-Week Range
- $1.09–5.48
- Bid/Ask
- $1.10 / $1.25
- Shares Outstanding
- 100.73M
- Market Cap
- $112.82M
- Volume/Avg
- 217 / 82,665
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.95
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 229
- Website
- https://www.cellectis.com
Valuation
|
Metric
|
CLLS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.70 |
Price/Sales | 1.95 |
Price/Cash Flow | — |
Price/Earnings
CLLS
Financial Strength
|
Metric
|
CLLS
|
|---|---|
Quick Ratio | 1.34 |
Current Ratio | 1.37 |
Interest Coverage | −8.09 |
Quick Ratio
CLLS
Profitability
|
Metric
|
CLLS
|
|---|---|
Return on Assets (Normalized) | −23.36% |
Return on Equity (Normalized) | −98.47% |
Return on Invested Capital (Normalized) | −44.58% |
Return on Assets
CLLS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|nbNTPJ | LOCK|!fLf | $126B | |||
| Moderna Inc
MRNA
| LOCK|C#gfx$N | LOCK|h? | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|M>^^l& | LOCK|Js&M | $80B | |||
| argenx SE ADR
ARGX
| LOCK|#K<g^cm | LOCK|%hz | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|s@!h@j | LOCK|g# | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>?M#FK$ | LOCK|gf<>! | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&?gch%K | LOCK|Bk!@z | $26B | |||
| Incyte Corp
INCY
| LOCK|&qRp^b | LOCK|$lY | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|B@t@v? | LOCK|?@$ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|n?y?%% | LOCK|lf | $14B |
United States